Copying in Patent Law

Christopher A. Cotropia

University of Richmond, ccotropi@richmond.edu

Follow this and additional works at: http://scholarship.richmond.edu/law-faculty-publications

Part of the Intellectual Property Law Commons

Recommended Citation

This Article is brought to you for free and open access by the School of Law at UR Scholarship Repository. It has been accepted for inclusion in Law Faculty Publications by an authorized administrator of UR Scholarship Repository. For more information, please contact scholarshiprepository@richmond.edu.
COPYING IN PATENT LAW*

CHRISTOPHER A. COTROPIA** AND MARK A. LEMLEY***

Patent law is virtually alone in intellectual property (IP) in punishing independent development. To infringe a copyright or trade secret, defendants must copy the protected IP from the plaintiff, directly or indirectly. But patent infringement requires only that the defendant's product falls within the scope of the patent claims. Not only doesn't the defendant need to intend to infringe, but the defendant may be entirely unaware of the patent or the patentee and still face liability.

Nonetheless, copying does play a role in some subsidiary patent doctrines, including damages rules, willfulness, and obviousness. More significantly, the rhetoric of patent law (and of IP law more generally) often seems to presuppose that defendants in patent cases are in fact engaged in copying. Similarly, the outcome of public policy debates over patent reform may well turn on the perception of patent infringers as either bad actors or as innocent businesspeople who accidentally ran afoul of a patent.

Unfortunately, no one seems to know whether patent infringement defendants are in fact unscrupulous copyists or independent developers. In this paper, we seek to answer that

* © 2009 by Christopher A. Cotropia and Mark A. Lemley.
** Professor, Intellectual Property Institute, University of Richmond School of Law.
*** William H. Neukom Professor, Stanford Law School; Partner, Durie Tangri LLP.

We thank the Kauffman Foundation for research support, the Stanford IP Litigation Clearinghouse for providing us with the complaint sample, Michael Barclay, Robert Barr, Dawn-Marie Bey, Colleen Chien, Dennis Crouch, John Golden, Rose Hagan, Paul Heald, Andy Litteral, Rafael Pardo, Cecil Quillen, Arti Rai, Carl Shapiro, Ted Sichelman, Katherine Strandburg, Sam Vermont, and participants in workshops at the Kauffman Foundation, Berkeley Law School, and Stanford Law School for comments on an earlier draft, and Sarah Craven and Vinita Kailasanath for outstanding research assistance. We give special thanks to Andrew Chin, Lolly Gasaway, and the North Carolina Law Review staff for giving us the opportunity to present this paper at the Frontiers in Empirical Patent Law Scholarship Symposium and the participants at the Symposium for their comments.
question. We look both at the allegations made in a random sample of complaints and at the treatment of copying in recent reported decisions, including willfulness decisions. We find that a surprisingly small percentage of patent cases involve even allegations of copying, much less proof of copying. Copying in patent law seems to be very much the exception, not the rule, except in the pharmaceutical industry.

INTRODUCTION .............................................................................................................. 1423
I. COPYING'S CURRENT PLACE IN PATENT DOCTRINE ...................... 1424
   A. Copying Is Not Required to Prove Liability ................................. 1425
   B. Copying Plays a Role in Other Patent Doctrines .................... 1428
      1. Copying as an Element of Specific Patent Doctrines ........ 1428
      2. Copying as a Foundation for Particular Patent Theories .......... 1431
         a. The Disclosure Bargain and Improvement Theory .................. 1431
         b. Design-Around Theory ..................................................... 1434
         c. Doctrine of Equivalents Theory ........................................ 1435
      3. Copying as a Rhetorical Device ............................................. 1436
   C. Reforms to Copying's Role in Patent Law ............................... 1437
II. THE SCARCITY OF COPIERS IN PATENT CASES .................... 1439
   A. Allegations of Copying .......................................................... 1440
      1. Data Collection ............................................................... 1440
      2. Data on Allegations of Willfulness ................................... 1441
      3. Data on Allegations of Copying ...................................... 1443
   B. Court Findings of Copying ...................................................... 1449
      1. Data Collection ............................................................... 1449
      2. Data on Claims of Copying ............................................. 1451
      3. Data on Willful Infringement Findings .............................. 1453
   C. Interpreting the Data ............................................................. 1456
III. IMPLICATIONS OF THE DATA .................................................. 1458
   A. Understanding Policy Debates and Reform Proposals .......... 1458
   B. Calibrating Patent Damages ................................................... 1461
   C. Patents, Disclosure, and Technology Transfer ................... 1464
   D. Choosing Between Patents and Trade Secrets ....................... 1465
CONCLUSION ............................................................................................... 1466
INTRODUCTION

Patent law is virtually alone in intellectual property ("IP") law in punishing independent development. To infringe a copyright or trade secret, defendants must copy the protected IP from the plaintiff, directly or indirectly. But patent infringement requires only that the defendant's product falls within the scope of the patent claims. It's not just that patent law doesn't require any intent to infringe. The defendant may be entirely unaware of the patent or the patentee and still face liability for independently creating a similar work.

Nonetheless, copying does play a role in some subsidiary patent doctrines, as we discuss in Part I. For example, the question of whether patent damages should be set in order to deter infringement, rather than solely to compensate the patentee, depends critically on whether infringers are in fact aware they are infringing, or at least that they are using the plaintiff's technology. The definition of "willful infringement" turns on the question of culpability, at least in the popular understanding of that term. Copying—or at least intent to infringe—is also an element of claims for indirect infringement. More significantly, the rhetoric of patent law (and of IP law more generally) often seems to presuppose that defendants in patent cases are in fact engaged in copying. Similarly, the outcome of public policy debates over patent reform may well turn on the perception of patent infringers as either bad actors or as innocent businesspeople who accidentally ran afoul of a patent.

Unfortunately, no one seems to know whether most patent infringement defendants are in fact unscrupulous copyists or independent developers. In this Article, we seek to shed light on that question. Because copying is not an element of any patent cause of action, courts do not normally make explicit findings as to whether defendants have copied. Instead, we turn in Part II to a variety of

1. The Copyright Act defines the rights as ones involving a "copy" of a protected work, 17 U.S.C. § 106 (2006), and courts are unanimous in requiring proof of copying, though that copying need not be intentional or even conscious. See ROBERT P. MERGES ET AL., INTELLECTUAL PROPERTY IN THE NEW TECHNOLOGICAL AGE 476–82 (rev. 4th ed. 2007). Similarly, trade secret law requires that the secret be acquired from the plaintiff, and makes independent development a defense. UNIF. TRADE SECRETS ACT § 1, cmt. 1, 14 U.L.A. 529, 538 (2000) ("Proper means include ... [d]iscovery by independent invention."); RESTATEMENT (THIRD) OF UNFAIR COMPETITION § 43 (1995). For our definition of copying, see infra notes 24–30 and accompanying text.
2. See infra notes 36–37 and accompanying text (detailing copying's relevance in a claim of indirect infringement).
proxies to try to identify the subset of cases in which copying is alleged or proven. We look both at the allegations made in a random sample of complaints and at the treatment of copying in recent reported decisions.

We find that a surprisingly small percentage of patent cases involve even allegations of copying, much less proof of copying. Only 10.9% of the complaints studied—21 of 193 complaints—contained even an allegation that the defendant copied the invention, either from the patent or from the plaintiff’s commercial product. This percentage is even lower when looking at published decisions, with 6.89% of the decisions—129 of 1871 cases—including an allegation of copying. Copying was found in 33 of these cases, meaning that copying was established in only 1.76% of all cases in our dataset. Copying seems to be the exception, not the rule in patent cases. And our data indicates that copying is particularly rare outside of the pharmaceutical and chemical arts. Pharmaceutical and chemical cases constitute more than half of the allegations of copying in both complaints and decisions and two-thirds of the reported findings of copying. In other industries, such as computers and software, less than 3% of cases involve allegations of copying, and less than 1% involve proof of copying.

Our findings have significant implications for both patent theory (which often depends on assumptions about the role of patent disclosure and improvements) and patent policy. In particular, we caution against the modern trend of treating infringers as bad actors when assessing damages; overwhelmingly, they are not. We discuss these and other implications in Part III.

I. COPYING’S CURRENT PLACE IN PATENT DOCTRINE

One of the most significant differences between patent law and other areas of intellectual property is that, in patent law, copying is irrelevant to the determination of infringement.\(^3\) It is axiomatic that patent infringement is a “strict liability offense.”\(^4\) However, many components of patent law, patent theory, and even the rhetoric used

---

3. See Stephen M. Maurer & Suzanne Scotchmer, The Independent Invention Defence in Intellectual Property, 69 ECONOMICA 535, 535 (2002) (“Perhaps the most basic difference between patents and other intellectual property such as trade secrets and copyright is that independent invention is not a defence to infringement.”).

in patent cases make copying a relevant consideration. Proposed reforms to the patent system would make copying even more directly relevant.

A. Copying is Not Required to Prove Liability

Courts assess patent infringement by comparing the allegedly infringing product or process to the patent’s claims. An individual literally infringes if her technology practices each and every element of the claimed invention. Patent law requires nothing more. Questions of infringement do not focus on the alleged infringer’s intent. Nor does infringement require evidence of copying the patent or commercial embodiments of the patented invention. For the initial liability determination in patent law, an “innocent” infringer is treated the same as an individual who copied the patented technology. Put simply, copying is irrelevant to the issue of liability.

Nor is copying relevant to the determination of infringement under the doctrine of equivalents. Determining whether the alleged infringer’s actions, while not falling within the literal scope of the claims, are equivalent to the claimed subject matter does not involve an inquiry into the infringer’s state of mind or actions of copying. The Supreme Court of the United States has specifically held that copying (or its absence) is irrelevant to infringement under the doctrine of equivalents.

Accordingly, in patent law, an individual who develops an already-patented technology without knowledge of the patent and the

8. See Allen Eng’g, 299 F.3d at 1351; Merges & Duffy, supra note 7, at 781 (noting that 35 U.S.C. § 271 “does not require any proof of access to the inventor’s work”).
9. Allen Eng’g, 299 F.3d at 1351 (indicating that copying is irrelevant to the equivalents inquiry).
technology's prior creation—a true "independent inventor"—is still liable if what she independently created falls within the scope of the patent's claims. Liability of an independent inventor turns solely on the question of timing, not the independent nature of the second inventor's actions. As long at the patent's inventor was the first to invent the claimed technology, she can exclude anyone else who develops the claimed technology, independently or not. The first individual to conceive of the invention—that is, mentally visualize the complete invention—has superior rights to all future developers as long as she is diligent in either bringing her invention to the patent office or actually reducing the invention to practice from the time of conception by another inventor. The second conceiver can even be the first to put the invention to actual use and still be considered an infringer.

The lack of a copying requirement for liability places patent law in sharp contrast with copyright and trade secret law. Copyright law, as its name connotes, requires an individual to copy the protected work to be found liable. While doctrines such as subconscious

11. See MERGES & DUFFY, supra note 7, at 781.
12. "Conception is the ‘formation in the mind of the inventor, of a definite and permanent idea of the complete and operative invention, as it is hereafter to be applied in practice.’" Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1376 (Fed. Cir. 1986) (quoting 1 ROBINSON ON PATENTS 532 (1890)). "Conception is the touchstone of inventorship . . . .." Burroughs Wellcome Co. v. Barr Labs., Inc., 40 F.3d 1223, 1227-28 (Fed. Cir. 1994).
13. 35 U.S.C. § 102(g) (2006) (defining the standard for determining priority between two inventors of the same technology); Cooper v. Goldfarb, 154 F.3d 1321, 1327 (Fed. Cir. 1998) (articulating the standard in reverse and noting that "priority of invention goes to the first party to reduce an invention to practice unless the other party can show that it was the first to conceive of the invention and that it exercised reasonable diligence in later reducing that invention to practice"); MERGES & DUFFY, supra note 7, at 440-41. Reduction to practice is established by either actually implementing the invention or filing an enabling patent application. See Medichem, S.A. v. Rolabo, S.L., 437 F.3d 1157, 1169 (Fed. Cir. 2006). An actual reduction to practice that has been "abandoned, suppressed, or concealed" does not count for priority purposes. 35 U.S.C. § 102(g).
14. Again, this holds true as long as the first conceiver is diligent from the "time prior to the conception by the other." 35 U.S.C. § 102(g).
15. See Arinstein v. Porter, 154 F.2d 464, 468-69 (2d Cir. 1946). Some circuits allow copying to be established by a "striking similarity" between the protected work and infringing works, even if there is no evidence that the alleged infringer had any access to the copyrighted work. Gaste v. Kaiserman, 863 F.2d 1061, 1067-68 (2d Cir. 1988). But see Selle v. Gibb, 741 F.2d 896, 901 (7th Cir. 1984) (requiring proof of access even with a finding of striking similarity). Under such a test, some might argue that copying is not required to establish copyright infringement. However, the rationale for relying solely on striking similarity is that such evidence "preclude[s] the possibility of independent
copying potentially remove the state of mind from the copying requirement, actual copying is still a fundamental first step in determining copyright infringement.

Trade secret law is similar, requiring an individual to misappropriate the trade secret to be held liable. Misappropriation occurs when the trade secret is obtained through improper means or through a breach of confidence. Either trigger for liability entails a "copying" of the trade secret. The infringer obtains the information from someone else—in most cases the trade secret’s creator. And while trade secret law does preclude the use of information acquired by accident or mistake, the information must still be acquired from the trade secret owner and used with knowledge that it was inadvertently disclosed. By contrast, independent creation of the information, through normal means or reverse engineering, is a complete defense against a trade secret allegation.

Trademark law occupies a middle ground. Trademark infringement is based upon a finding of likely consumer confusion, which can occur without copying of the mark by the defendant. But intent to copy or deceive is one of the factors courts use in deciding consumer confusion, and recent work by Barton Beebe has found...
that, in fact, evidence of intent is the most significant factor predicting a finding of trademark infringement. So, as a practical matter, trademark infringement usually involves copying, or at least a defendant's awareness of the plaintiff's mark. Patent law, then, stands alone among IP rights in not requiring or at least not strongly weighing evidence of copying.

B. Copying Plays a Role in Other Patent Doctrines

While copying isn't necessary for infringement, the existence of copying is not completely irrelevant in patent law. Many doctrines outside of the initial determination of infringement consider whether the alleged infringer or a third party has copied the patented technology. Some patent theory assumes, as a precondition, that others will copy the patented technology. Finally, much of the rhetoric used by courts and commentators when discussing patent infringement invokes the concepts of a copier and copying when identifying the infringer and describing her actions.

1. Copying as an Element of Specific Patent Doctrines

Whether a finding of patent infringement was the result of copying is relevant to the question of willful infringement and the accompanying enhancement of damages. "Willful infringement is . . . a measure of reasonable commercial behavior in the context of the tort of patent infringement." The act of copying the patented technology evidences the infringer's "disregard[] for the property rights of the patentee" and "the deliberateness of the tortious acts." Patent law views such copying as "reprehensible" and, in turn, worthy of enhancement.

---

23. Barton Beebe, An Empirical Study of the Multifactor Tests for Trademark Infringement, 94 CAL. L. REV. 1581, 1608 (2006) ("The court found an intent to confuse consumers in sixty-seven opinions. In sixty-five (97%) of these opinions, the court found an overall likelihood of confusion.").

24. See In re Seagate Tech. LLC, 497 F.3d 1360, 1368 (Fed. Cir. 2007) (en banc) ("Because patent infringement is a strict liability offense, the nature of the offense is only relevant in determining whether enhanced damages are warranted."); Knorr-Bremse Systeme Fuer Nutzfahrzeuge GmbH v. Dana Corp., 383 F.3d 1337, 1348-49 (Fed. Cir. 2004) (en banc). A finding of willfulness is required to enhance damages but does not require such an enhancement. Seagate, 497 F.3d at 1368.


26. Id.
of punitive damages in the form of enhanced damages.\textsuperscript{27} Courts have even justified raising a reasonable royalty award to compensate for copying despite a finding that the infringement wasn't willful.\textsuperscript{28} Notably, while copying is \textit{evidence} of willful infringement, copying is not \textit{required} to prove willful infringement.\textsuperscript{29} In fact, as we shall see, most willfulness claims do not involve allegations of copying at all. Nor does evidence of copying, by itself, mean the infringement is willful.\textsuperscript{30}

Copying is also relevant to the issue of patent validity as a secondary consideration of nonobviousness.\textsuperscript{31} Copying of the patented invention by the infringer or a third party is seen by patent law as an indicator that the invention is nonobvious.\textsuperscript{32} The rationale is that a competitor engages in such copying only if they need a solution to the problem the invention addresses and they cannot come up with one on their own.\textsuperscript{33} Patent law also assumes that others copy only those inventions of technical value.\textsuperscript{34} Both of these assumptions based on the existence of copying are indicators that the

\begin{itemize}
\item \textsuperscript{27} \textit{Knorr-Bremse}, 383 F.3d at 1348–49.
\item \textsuperscript{28} See, e.g., \textit{Monsanto Co. v. McFarling}, 488 F.3d 973, 980 (Fed. Cir. 2007) (expressing a concern that a reasonable royalty that is too low would "create a windfall for infringers" who intentionally engage in unauthorized use of the patented technology; the court in that case had rejected a willfulness claim).
\item \textsuperscript{29} See, e.g., \textit{Underwater Devices, Inc. v. Morrison-Knudsen Co.}, 717 F.2d 1380, 1389–90 (Fed. Cir. 1983) (setting out a multi-factor test to use in considering willfulness).
\item \textsuperscript{30} \textit{Id}.
\item \textsuperscript{31} See \textit{Apple Computer, Inc. v. Articulate Sys., Inc.}, 234 F.3d 14, 26 (Fed. Cir. 2000); \textit{Specialty Composites v. Cabot Corp.}, 845 F.2d 981, 991 (Fed. Cir. 1988) (stating that the copying of the "claimed invention, rather than one in the public domain, is indicative of nonobviousness" (quoting \textit{Windsurfing Int'l, Inc. v. AMF, Inc.}, 782 F.2d 995, 1000 (Fed. Cir. 1986))).
\item \textsuperscript{32} \textit{Advanced Display Sys., Inc. v. Kent State Univ.}, 212 F.3d 1272, 1285–86 (Fed. Cir. 2000) (citing the infringer's copying of the patented invention as evidence of nonobviousness).
\item \textsuperscript{33} See \textit{Dow Chem. Co. v. Am. Cyanamid Co.}, 816 F.2d 617, 622 (Fed. Cir. 1987); \textit{Vandenberg v. Dairy Equip. Co.}, 740 F.2d 1560, 1567 (Fed. Cir. 1984) ("The copying of an invention may constitute evidence that the invention is not an obvious one. . . . This would be particularly true where the copyist had itself attempted for a substantial length of time to design a similar device, and had failed."); Christopher A. Cotropia, \textit{Nonobviousness as an Exercise in Gap Measuring}, in \textit{2 INTELLECTUAL PROPERTY AND INFORMATION WEALTH} 21, 32 (Peter K. Yu ed., 2007) ("A competitor only engages in copying if they need a solution to the problem the invention addresses and they cannot come up with a solution on their own."). That rationale is open to question, however. A company may copy an invention not because it had no choice, but because it thought the invention was unpatented or unpatentable and therefore free to be used without need for reinvention.
\item \textsuperscript{34} See Cotropia, supra note 33, at 32.
\end{itemize}
invention meets the nonobviousness requirement and is worthy of patent protection.\textsuperscript{35}

Third, copying is relevant to some claims for indirect infringement. Specifically, the Federal Circuit has made it clear that a defendant is not liable for inducing infringement by another unless it intended that the conduct it induced infringe a known patent.\textsuperscript{36} An inducement claim doesn’t necessarily involve copying—a defendant might independently develop a technology, then learn of a patent covering it, and still encourage another to infringe that patent. However, the fact that inducement requires both knowledge of the patent and intent to encourage infringement means that inducement is more likely than ordinary infringement cases to involve allegations of copying.\textsuperscript{37}

Finally, as an exception to the general rule that copying is irrelevant to the question of liability, an accusation of infringement under 35 U.S.C. § 271(e)(2)(A) almost by definition involves acts of copying. Section 271(e)(2)(A) allows a patent holder to sue a generic drug manufacturer who files an abbreviated new drug application ("ANDA") that contains a paragraph IV certification.\textsuperscript{38} Such a certification alleges that the previously approved drug to which an ANDA pertains is covered by patents that are invalid or will not be infringed by the generic drug.\textsuperscript{39} In order to file a proper and successful ANDA, the generic drug manufacturer must "copy" the original drug—the generic’s active ingredient must be the bioequivalent of the listed drug.\textsuperscript{40} These sets of facts that give rise to

\textsuperscript{35} See id. (concluding that copying provides second-order evidence that the technology gap between the prior art and the invention is such that patent protection is warranted).

\textsuperscript{36} See DSU Med. Corp. v. JMS Co., 471 F.3d 1293, 1305-06 (Fed. Cir. 2006).

\textsuperscript{37} Contributory infringement, by contrast, requires knowledge of the existence of the patent but not specific intent to infringe. Aro Mfg. Co. v. Convertible Top Replacement, Co., 377 U.S. 476, 488-89 (1964). These claims too must involve awareness of the patentee’s technology but are less likely to involve copying.

\textsuperscript{38} See 35 U.S.C. § 271(e)(2)(A) (2006); Bayer AG v. Elan Pharm. Research Corp., 212 F.3d 1241, 1245 (Fed. Cir. 2000). “A charge of infringement under § 271(e)(2) is technical in nature” given that the ANDA filer has only sought FDA approval. SCHECHTER & THOMAS, supra note 5, at 287.


\textsuperscript{40} An ANDA is proper only if the generic drug's active ingredient is the "bioequivalent" of the already approved drug. See 21 U.S.C. § 355(j)(2)(A)(iv). A generic drug is bioequivalent if the extent and rate of absorption of the drug are not significantly different from that of the already approved drug. See § 355(j)(8)(B)(i).
a § 271(e)(2) allegation of infringement mean that the generic drug producer has copied the patent holder's technology. 41 It does not, however, necessarily mean that the patented invention was copied; the patent might cover something other than the active ingredient to which the generic is bioequivalent. 42

2. Copying as a Foundation for Particular Patent Theories

Copying also plays a role in a number of patent theories. The idea that a patent constitutes a bargain with the public, in which the patentee gets exclusivity for a limited time in exchange for giving the public information about the invention, presupposes that companies will read and learn from the patent in order to copy the invention (albeit after the patent has expired). Improvement theory assumes that one of the patent law's benefits is that others refer to the patent document and the technology it describes in order to build upon that technology. Design-around theory assumes that others read patents in order to create competing, noninfringing alternatives to the patented technology. The doctrine of equivalents is also grounded in the assumption that defendants copy from patent owners. One view of that doctrine is that it is meant to catch the "unscrupulous copyist" who has set out to copy the patented technology and makes a minor change in order to avoid infringement via a technicality.

a. The Disclosure Bargain and Improvement Theory

The improvement theory of patent law describes patenting as a mechanism to both assist and prompt others to develop

41. See, e.g., Abbott Labs. v. Young, 920 F.2d 984, 991 (D.C. Cir. 1990) (Edwards, J., dissenting) (noting that the ANDA process "emerged from Congress' efforts to balance two conflicting policy objectives: to induce name brand pharmaceutical firms to make the investments necessary to research and develop new drug products, while simultaneously enabling competitors to bring cheaper, generic copies of those drugs to market"); Takeda Chem. Indus., Ltd. v. Mylan Lab., Inc., 459 F. Supp. 2d 227, 231 (S.D.N.Y. 2006) ("When filing the ANDA the applicant must make a certification regarding any patent protecting the drug that will be copied.").

42. An ANDA could be filed by an independent drug developer who was second to invent and must therefore go through the ANDA process to produce and sell the new pharmaceutical. This ANDA filer must still, however, claim bioequivalence. As a practical matter, this is a very uncommon occurrence. See, e.g., Gerald J. Mossinghoff, Overview of the Hatch-Waxman Act and Its Impact on the Drug Development Process, 54 FOOD & DRUG L.J. 187, 194 (1999) (noting that the main purpose behind the ANDA process is to encourage generic drug manufacturers to enter the market).
improvements to the already-patented technology.\textsuperscript{43} The patent disclosure, which is required to be enabling, provides technical information about the claimed invention.\textsuperscript{44} This technical information is publicly available and readily accessible, allowing anyone to both learn about the patented technology and then use this information to copy the invention once the patent expires or to create an improvement during the patent term.\textsuperscript{45} Building upon existing patented technology is a fundamental aspect of the patent system, and such improvements are crucial to technological advancement.\textsuperscript{46}

When such improvements are patented, another fundamental concept in patent law comes into play—blocking patents. The blocking patent's story begins with an inventor developing and patenting a base technology and then an improver building upon that base technology and patenting the improvement.\textsuperscript{47} This situation gives rise to two patents—one covering the base technology and one covering the improvement. Any party wishing to practice the improvement must get licenses from both the original developer and


\textsuperscript{44} 35 U.S.C. § 112, ¶ 1 (2006) (setting forth the requirement that the patent disclosure enable the claimed invention); Sitrick v. Dreamworks, LLC, 516 F.3d 993, 999 (Fed. Cir. 2008) (describing the enablement requirement in patent law, which requires that "one skilled in the art, after reading the specification, could practice the claimed invention without undue experimentation").


the improver. The availability of patent protection for the improver, which creates the blocking patent, encourages the creation of the improvement because of the bargaining power patent exclusivity gives to the improving inventor. In the end, patent law facilitates the creation of improvements by both communicating the existence and technical details of the base technology and then providing patent protection for any patentable improvements that are developed.

The theory that the patent system facilitates and encourages improvements assumes that potential improvers learn about the base technology from either the patent itself or a commercial embodiment of the patented invention. The improver is viewed as leveraging off of the earlier patent’s technical description, and, in some instances, actually communicating and coordinating with the developer of the base technology. This all assumes some level of copying, or, at the very least, an awareness of the base technology and patent that sparks some modification to what has already been done. If there is no copying, then there is no improving from the viewpoint of the follow-on inventor. She is, from her perspective, starting from scratch.

For the patent system to play a role in improving technology, the base technology the system encourages must be known and used in some way by the improver. If she has not copied, her invention is not an improvement at all, but independent development of a better alternative (a “leapfrogging” invention).

---

48. Lemley, supra note 47, at 1010 (“The original patent owner can prevent the improver from using his patented technology, but the improver can also prevent the original patent owner from using the improvement. Unless the parties bargain, no one gets the benefit of the improvement.”).

49. See id. at 1013. This power is by no means absolute, and a bargaining breakdown could nullify the benefit of the blocking patent. See Robert Merges, Intellectual Property Rights and Bargaining Breakdown: The Case of Blocking Patents, 62 TENN. L. REV. 75, 82–91 (1994) (detailing and providing real-world examples of the bargaining breakdown between the base and improvement patent holders).

50. This is not to say that a new technology is only an “improvement” if the improver actually references and uses an earlier technology in development of the new technology. Even if she thinks she is “starting from scratch,” the result is still objectively an improvement to the earlier technology. State of mind is irrelevant to the definition of improvement. However, patent law’s improvement theory focuses on the earlier category of improvements—ones in which the improver actually uses the base technology as the starting point for the new technology.
b. Design-Around Theory

Design-around theory is a subset of the improvement theory. The theory is that the patent system sparks a specific type of "improvement"—a substitute to the patented technology that does not infringe the patent.51 A competitor, faced with the possibility of infringing the patent in order to compete in a given industry, reads the patent in order to determine how they can "design-around" the boundaries of the patent’s claims.52 The patent, by promoting the creation of a commercial substitute through this design-around process, is socially beneficial.53 The Federal Circuit has acknowledged that encouraging design-arounds is a goal of the patent system: “One of the benefits of a patent system is its so-called ‘negative incentive’ to ‘design around’ a competitor’s products, even when they are patented, thus bringing a steady flow of innovations to the marketplace.”54

The design-around theory, like the improvement theory, assumes that the competitor who chooses to design around is aware of and working from the plaintiff’s patent. Here, the theory assumes that the competitor reads the patent’s claims when designing a competing product with the goal of making sure that the developed product does not fall within the patent’s exclusivity. A successful design-around does not copy every element of the claimed technology; one might question whether they are really "copying" at all. But one who designs around an invention necessarily refers to and uses the patented invention in developing the competing product or process, and often uses the patented invention in the course of developing the noninfringing alternative.55

51. See Slimfold Mfg. Co. v. Kinkead Indus., Inc., 932 F.2d 1453, 1457 (Fed. Cir. 1991) ("Designing around patents is... one of the ways in which the patent system works to the advantage of the public in promoting progress in the useful arts, its constitutional purpose.").
52. See Nard, supra note 43, at 40-41 ("As the term ‘design-around’ suggests, a competitor of the patentee may purposefully circumvent the boundaries of the patent claim and create a competitive, noninfringing alternative to the claimed invention.").
53. Id.
55. As Carl Shapiro has pointed out to us, design-arounds standing alone aren’t socially valuable; it is the improvements they spark that the law really wants to encourage.
c. Doctrine of Equivalents Theory

One justification for the doctrine of equivalents also assumes copying by potential infringers. As has already been mentioned, the U.S. Supreme Court specifically dismissed evidence of the infringer's copying of the patented invention (or alternatively, of the infringer's efforts to design around the invention) as irrelevant to the doctrine of equivalents inquiry.\textsuperscript{56} But the early judicial rationale behind the doctrine of equivalents built upon concepts of fairness and equity to justify the doctrine's existence.\textsuperscript{57} The Supreme Court concluded that limiting protection to the claim's literal scope allowed someone "to make unimportant and insubstantial changes and substitutions in the patent which, though adding nothing, would be enough to take the copied matter outside the claim, and hence outside the reach of law."\textsuperscript{58} Denying the patentee access to the doctrine of equivalents "would leave room for—indeed encourage—the unscrupulous copyist."\textsuperscript{59}

This reasoning assumes that there are individuals who target patented technologies, looking to appropriate the core value of the invention but to avoid being found liable for patent infringement by making minor variations. While this is not the only rationale for the doctrine,\textsuperscript{60} courts today, when discussing the rationale behind the doctrine of equivalents, still refer to the doctrine as a means to capture copiers.\textsuperscript{61}

\textsuperscript{58.} Graver Tank & Mfg. Co. v. Linde Air Prods. Co., 339 U.S. 605, 607 (1950); see also Warner-Jenkinson, 520 U.S. at 36 ("[O]ne wonders how to distinguish between the intentional copyist making minor changes to lower the risk of legal action, and the incremental innovator designing around the claims, yet seeking to capture as much as is permissible of the patented advance.").
\textsuperscript{59.} Graver Tank, 339 U.S. at 607.
\textsuperscript{60.} See Cotropia, supra note 57, at 160–62 (noting the current emphasis on a utilitarian theory of the doctrine and a focus on after-arising technologies); Meurer & Nard, supra note 57, at 1967–68 (describing the modern "friction theory" of the doctrine of equivalents).
\textsuperscript{61.} See, e.g., Trading Techs. Int'l, Inc. v. eSpeed, Inc., 507 F. Supp. 2d 854, 860-61 (N.D. Ill. 2007) (quoting Graver Tank's copying discussion to describe the "import of the doctrine of equivalents").
3. Copying as a Rhetorical Device

The concept of copying also plays a role in the rhetoric used by courts and commentators when discussing patent infringement. An infringer of a patent claim is often said to have “copied” the invention and, in turn, is labeled a “copier” or “copyist.” This terminology is used even when the infringer actually independently developed the infringing product or process. Likewise, an independent invention is often identified as a “copy” of an earlier patent though technically it was independently created. Such rhetoric even rises to the level of labeling the infringer a “thief” or their actions “stealing.”

The use of the term copying and its derivatives to characterize infringement is notable, given that patent law does not premise infringement on copying. The law places heavy weight on language; in turn, courts and commentators have an obligation to use language accurately. The linguistic slide from “infringer” to “copier” to “thief” presupposes that anyone who infringes is also copying and therefore stealing. That is an empirical proposition—and, as we show in Part II, a false one. Second, terms such as copying come with heavy baggage. They are loaded—“carry[ing] an undercurrent of disapproval, of

---

62. See, e.g., SPX Corp. v. Bartec USA, LLC, 530 F. Supp. 2d 914, 919 (E.D. Mich. 2008) (characterizing the allegation as one that “Bartec USA, LLC (Bartec) copied [the patented] design for a handheld tool used in servicing tires on motor vehicles equipped with remote tire monitoring systems,” even though no actual allegation of copying was identified) (emphasis added).


65. See, e.g., Sanitary Refrigerator Co. v. Winters, 280 U.S. 30, 41–42 (1929) (“There is a substantial identity, constituting infringement, where a device is a copy of the thing described by the patentee . . . .”).


67. See, e.g., Royal Typewriter Co. v. Remington Rand, Inc., 168 F.2d 691, 692 (2d. Cir. 1948) (Hand, J.) (identifying the doctrine of equivalents as a vehicle to “prevent an infringer from stealing the benefit of the invention”).
unfavorable practices, of ‘it’s just not on.’”68 Allowing the use of the terms is particularly detrimental in jury cases because “a juror’s everyday experience, stemming from earliest school days, generates the lay biases and pejorative flavor the word ‘copy’ carries.”69 Finally, copying rhetoric is important because it may reflect reality or, if repeated enough, become reality. Scholars in the patent area have focused before on rhetoric as an indicator of what was70 or of what is coming.71

C. Reforms to Copying’s Role in Patent Law

Finally, a number of commentators and legislators have proposed reforms that give copying a larger role in patent law. These reforms target copying’s role in determining infringement and take the form of various degrees of independent inventor defenses.

In its purest form, an independent inventor defense absolves any patent infringer of liability unless the infringement resulted from copying the claimed invention. That is, “independent conception of the invention and independent reduction of it to practice” would be a complete defense to infringement.72 Such an absolute defense does not exist in the United States.

Stephen Maurer and Suzanne Scotchmer articulate two advantages to an independent inventor defense.73 First, the threat of market entry by an independent inventor forces the patent holder to license at a lower price, reducing deadweight loss.74 In addition, the availability of an independent inventor defense also “reduces entry

---

69. Id.
71. See, e.g., Mark A. Lemley, Property, Intellectual Property, and Free Riding, 83 TEX. L. REV. 1031, 1033–41 (2005) (relying on the rising rate of court usage of the terms “intellectual property” and “free riding” as evidence that courts are viewing intellectual property more and more as a species of real property).
73. Maurer & Scotchmer, supra note 3, at 545. Vermont criticized Maurer & Scotchmer’s analysis because it “assum[ed] a potential [independent inventor] can evaluate a patented invention and still invent independently.” Vermont, supra note 72, at 482.
74. Maurer & Scotchmer, supra note 3, at 545.
into the [patent] race, and thus reduces wasteful duplication."\footnote{75} One of their only concerns with such a defense is that "fraudulent claims of independence may be undetectable."\footnote{76}

Samson Vermont argues for a modified independent inventor defense.\footnote{77} Vermont's major modification is to limit the defense to instances where there is no actual or constructive notice of the patent.\footnote{78} Actual notice entails the infringer seeing the invention before developing the infringing technology.\footnote{79} Constructive notice is satisfied by the publication of an enabling disclosure of the invention.\footnote{80} With the availability of constructive notice, a truly independent inventor who never sees the invention may still be denied the defense because of constructive notice. Vermont argues that such a defense reduces certain "system costs" while not detrimentally lowering the patent system's incentive to invent.\footnote{81} Finally, Carl Shapiro has offered a sophisticated economic justification for prior user rights (a variant on the independent inventor defense).\footnote{82}

Not all analyses of an independent inventor defense are positive. One of the authors of this Article, while not rejecting independent invention out of hand, articulated some concerns with the defense.\footnote{83} First, the number of significant inventions that have occurred in a multiple, independent inventor setting means that an independent

\begin{footnotesize}
\footnote{75. Id.} \\
\footnote{76. Id. at 544.} \\
\footnote{77. Vermont, supra note 72, at 484–89 (detailing the contours of a such a defense).} \\
\footnote{78. Vermont, supra note 72, at 485–87.} \\
\footnote{79. Id. at 485–86.} \\
\footnote{80. Id. at 486–87.} \\
\footnote{81. Id. at 493–500. The system costs saved include monopoly losses, rent dissipation, and other miscellaneous costs such as patent prosecution and litigation costs. Id. at 490–93.} \\
\footnote{83. Lemley, supra note 4, at 1525.}
\end{footnotesize}
invention defense would be a radical change in the patent system. Our data in this paper strengthens that conclusion. Second, there is a risk that the availability of the defense will reduce the incentive to invest in important technologies. This is particularly true if the barrier to invention is cost, not the uncertainty of the results. In addition, for certain industries, such as the pharmaceutical industry, "patent owners may need the power associated with a right of complete exclusion not just to encourage invention but to ensure that the inventor invests the resources to take the idea from invention through development to marketability."

An independent invention defense would focus the patent system on copying to some extent—absolutely in the case of a pure independent invention defense, and to a lesser extent if Vermont’s hybrid proposal were adopted.

Patent law, in short, does not require proof of copying. But much of the thinking about the patent system by courts, commentators, and the public is built on the assumption that defendants are in fact copying inventions from patent owners. In Part II, we put that assumption to the test.

II. THE SCARCITY OF COPIERS IN PATENT CASES

Because copying is not an element of patent cases, there is no specific requirement that plaintiffs plead or prove that the defendant has copied the invention, either from the patent itself or from the plaintiff’s commercial embodiment of the invention. Nonetheless, there is good reason to believe that plaintiffs will have strong incentives to plead and prove copying in cases where it exists. First, the fact that the defendant copied an invention from the plaintiff strongly suggests that the defendant’s product infringes the patent; while parties can and do fight about the meaning of patent claims, if the defendant actually derived its product from the plaintiff’s, it is likely to fit within any reasonable interpretation of most patent claims. Second, if the defendant copied from the plaintiff, that fact is likely to provide strong evidence that the defendant was a willful as

84. Id. at 1528 (citing such examples of simultaneous invention as the steamboat, airplane, and laser).
85. Id. at 1529.
86. Id. at 1530–31.
opposed to an innocent infringer, and therefore to justify an award of enhanced damages for infringement. The correspondence is not exact: a defendant may legitimately copy from the plaintiff if he has good reason to believe the patent is invalid—what the Federal Circuit has recently referred to as an objectively reasonable position. 88 But copying by the defendant is certainly evidence of willfulness that patent owners will want to submit where available. Third, as we noted in Part I, there are specific advantages patent owners can get by proving copying, such as using that fact as evidence of nonobviousness. Finally, plaintiffs who face the prospect of a jury trial (as the overwhelming majority do) 89 naturally want a good story to tell, and the story of theft is much more attractive than the story of inadvertent infringement.

To evaluate whether plaintiffs made claims of copying in patent cases, we studied complaints for patent infringement. To determine how those allegations fared, we studied written decisions that involve copying. The combined data give us a useful window into the extent of copying in patent litigation.

A. Allegations of Copying

1. Data Collection

To measure allegations of copying, we collected a sample of 200 patent infringement complaints filed between January 1, 2000 and May 1, 2007, 100 each from two districts, the District of Delaware and the Eastern District of Texas. Those districts have significantly different characteristics—Delaware is the corporate headquarters of a plurality of large companies and the base of operation of major chemical and pharmaceutical enterprises, while eastern Texas is mostly rural and has very little innovation, but has recently become the district with the most patent cases because of its plaintiff-friendly

---


reputation. Of those 200 cases, we excluded seven, four because the PACER data files were corrupted or unavailable, two because they in fact involved only trade secret claims or attempts to file suit on a not-yet-issued patent, and one that involved a design patent. As a result, our data set includes 193 useable cases.

For each of those 193 cases, we collected the initial complaint (if it was filed within our timeframe) as well as any amended complaints. We focused on amended complaints because it is possible that plaintiffs did not have evidence of copying when they filed their lawsuit, but later acquired such evidence; if so, it is reasonable to expect that some (if not all) of them would include that evidence in amended complaints. Our data set includes 179 initial complaints, 69 first amended complaints, 21 second amended complaints, and 8 third or more amended complaints.

2. Data on Allegations of Willfulness

Of the 193 cases, plaintiffs alleged willfulness in the overwhelming majority: 157, or 81.3%. This is roughly consistent
with Kimberly Moore's finding that willfulness was alleged in over 90% of cases. 93 While one might think this is evidence that at least plaintiffs believed copying was widespread, we cannot draw that conclusion because the legal definition of willfulness at the time these complaints were filed did not require proof of copying or even advance knowledge of the existence of the patent or the patent owner. 94 It was sufficient to show that the defendant didn't stop infringing once it found out about the patent and didn’t have good reason to believe that the patent was invalid or not infringed.

In fact, there is good reason to believe that the allegations of willfulness do not in fact reflect evidence of widespread copying. Of the 193 cases, only 60 (or 31.1%) involved allegations that the defendant was even aware of the patent before the lawsuit. It is common for patent plaintiffs to send a letter putting the defendant on notice of the existence of the patent; if the plaintiff did in fact send such a letter, we would expect the plaintiff to allege it, because in most cases patent damages begin to accrue only once the defendant receives such notice. 95 The fact that nearly 70% of plaintiffs don’t
even allege that the defendant was on notice of the patent at the time the lawsuit was filed suggests that the plaintiffs did not have evidence that the defendants in those cases had copied the patent. 96  Further, of the 98 amended complaints in our database, only 3 were amended to add allegations of willfulness, providing at least some inferential evidence that most claims of willfulness don’t involve actual knowledge of the defendant’s intent. Were it otherwise, we would expect to see willfulness pled later in the case rather than at the outset, after discovery into defendant’s intent. That doesn’t appear to happen.

3. Data on Allegations of Copying

When we investigated allegations that might correspond to actual copying, the results were even more dramatic. Barely 10% (21 of 193, or 10.9%) of the complaints we studied alleged that the defendant had copied the invention, either from the patent or from the plaintiff’s commercial product. 97  And we might think of this in some respects as an upper bound, because these include bare allegations that the defendant copied the invention. For example, we included in this category an allegation that the defendant has “built their system on use of [plaintiff’s] patents” and an allegation that defendant’s product is “a substantial copy” of plaintiff’s, both of which might be

---

96. That doesn’t mean the defendants in those cases didn’t actually copy, of course; just that the plaintiff had no basis on which to allege that they did, even as of the date of filing of the amended complaints.

97. The confidence interval for the percentage of complaints alleging copying is 15.27% > p > 6.49%. In our second sample of complaints, see supra note 92, twelve of the seventy-two complaints (16.67%) contained an allegation of copying. The confidence interval for the percentage of complaints in this second sample alleging copying is 24.47% > p > 7.53%. While the observed percentage of copying in the second sample falls outside the confidence interval of our initial sample, the two confidence intervals for the samples do overlap substantially. In addition, the percentage of allegations of copying in this second sample is still quite small, further substantiating our observations in this Article. The results of the second sample suggest that the actual percentage of complaints alleging copying may be higher than 10.9%, but not much higher.
general uses of the term “copy” or “use” to refer to similarity rather than derivation.98

Using this data, we can look at how related allegations of willfulness are to allegations of copying. In the 157 complaints alleging willfulness, 18 of those complaints also alleged copying (11.46%). Likewise, of the remaining 36 complaints not containing a willfulness allegation, 3 included an allegation of copying (8.33%). These two percentages are fairly similar, suggesting that there is no significant relationship between allegations of copying and allegations of willfulness. The result of a Fisher's Exact Test on the data confirms this finding, returning a p-value of 0.7077.99

Even more significant is the fact that 13 of the 21 cases alleging copying are pharmaceutical patents filed against generic ANDA filers. Because of the mechanics of the Hatch-Waxman Act, generic pharmaceutical defendants necessarily must copy the plaintiff’s active ingredient to achieve bioequivalence.100

The prevalence of ANDA cases in the small subset of cases that allege copying also points to another fact: whether patent plaintiffs allege copying depends on particular industries. In Table 1, we report

98. This demonstrates how broad a definition of an “allegation of copying” we used in our study—both when looking at complaints and opinions. Essentially, an allegation of any use of the patent or a commercial embodiment of the patented technology in the development of the allegedly infringing product or process was considered an allegation of copying, even though many such uses would not in fact be “copying” by most definitions. To be sure, there may be situations in which a defendant does not copy the plaintiff’s invention or even see it but nonetheless is indirectly influenced by it. If a defendant is aware that the plaintiff has succeeded in making the invention, for instance, but doesn’t know how, the mere knowledge that it can be done might itself be an aid to the defendant in developing its own product. We don’t class this as copying, though some might find it to be a “use” of the plaintiff’s invention in some sense.

99. This is the two-tail p-value. For the distribution to be statistically significant, a p-value must be less than 0.05. See DAVID FREEDMAN ET AL., STATISTICS 484 (3d ed. 1998). A p-value less than 0.01 is considered highly statistically significant. Id.

100. This proportion varies slightly in our second random sample. See supra note 97. Of the twelve instances of copying in this second sample, three are based on ANDA filings. That may reflect a smaller overall percentage of pharmaceutical cases in the second random sample, which excluded cases from Delaware, where many pharmaceutical patent cases are filed.
not only the overall data on copying but also the industry-specific data. 101

\textbf{Table 1:} Complaint Data By Industry

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmaceutical</td>
<td>20</td>
<td>17</td>
<td>12</td>
<td>13(^{102})</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Medical</td>
<td>8</td>
<td>6</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Biotechnology</td>
<td>10</td>
<td>6</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Computer-related</td>
<td>76</td>
<td>62</td>
<td>21</td>
<td>2</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Software</td>
<td>67</td>
<td>54</td>
<td>21</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Semiconductor</td>
<td>11</td>
<td>9</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Electronics</td>
<td>31</td>
<td>27</td>
<td>9</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Chemistry</td>
<td>25</td>
<td>22</td>
<td>16</td>
<td>14</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Mechanics</td>
<td>38</td>
<td>30</td>
<td>12</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Acoustics</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Optics</td>
<td>14</td>
<td>12</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Automotive</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Energy</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Communication</td>
<td>31</td>
<td>23</td>
<td>12</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td><strong>TOTALS</strong></td>
<td><strong>193</strong></td>
<td><strong>157</strong></td>
<td><strong>60</strong></td>
<td><strong>21</strong></td>
<td><strong>10</strong></td>
<td><strong>5</strong></td>
<td><strong>2</strong></td>
<td><strong>2</strong></td>
</tr>
</tbody>
</table>

As noted above, 10.9% of the overall cases allege copying. But the percentage of cases that allege copying by industry range from a low of 0% in optics and in semiconductors to a high of 65% in pharmaceuticals. 103 It is also worth noting that the two largest classes

101. We use the fourteen industry categories created and defined in John R. Allison & Mark A. Lemley, \textit{Who's Patenting What? An Empirical Exploration of Patent Prosecution}, 53 \textit{Vand. L. Rev.} 2099, 2110–12 (2000). Note that patents can and frequently do fit into more than one industry category, which is why the industry totals exceed the total number of patents.

102. Thirteen of sixteen ANDA cases involved allegations of copying; three other ANDA cases presumably involved copying but did not specifically allege it.

103. To avoid meaningless results, we report in text only the results for those industries with more than ten cases in our sample.

While the chemistry industry also produces a high result, 56% copying, that result is driven by the fact that most of the pharmaceutical cases are also chemistry cases. If we exclude pharmaceutical cases, there are only nine chemistry cases in the data set and only one (11%) alleges copying.
in our sample, computer-related inventions and software, have extremely low levels of alleged copying (2.6% and 3.0%, respectively).\textsuperscript{104} From this data, we observe a highly statistically significant difference between allegations of copying in pharmaceutical cases and similar allegations in computer-related and software cases.\textsuperscript{105} Allegations of copying are more likely in the chemical than in the IT industries.

To try further to parse these allegations of copying, we reviewed the complaints to determine what particular facts were alleged that might support an inference of copying. We found that 10 of the 193 complaints, or 5.2%, involved allegations of a prior business relationship between the firms, something that might plausibly have led to copying. Only 5 of the 193 complaints, or 2.6%, include an allegation of misappropriation of trade secrets, which necessarily requires an allegation of copying. And only 2 cases involve allegations of infringement by departing employees.\textsuperscript{106} None of these taken alone is particularly strong evidence; it is certainly possible that a defendant copied the plaintiff's invention in the marketplace or read the patent and used it to design its product, though the latter in particular would seem an odd business decision. And trade secret claims exist in some tension with patent claims, since one requires secrecy and the other requires disclosure.\textsuperscript{107} However, these data

\textsuperscript{104} The confidence interval for the percentage of pharmaceutical complaints alleging copying is $85.9\% > p > 44.1\%$. The confidence interval for the percentage of chemical complaints alleging copying is $75.46\% > p > 36.54\%$.

\textsuperscript{105} A Fisher's Exact Test gives a $p$-value $< 0.0001$. Since these industries commonly appear in pairs for a given invention—with pharmaceutical and chemical appearing together and computer-related and software appearing together—the observations of alleged copying were similarly paired and placed in a 2x2 table when performing the Fisher's Exact Test.

\textsuperscript{106} These numbers can't merely be added together; the two departing employee cases, for example, are also two of the cases that involve trade secret claims.

\textsuperscript{107} See Ferroline Corp. v. General Aniline & Film Corp., 207 F.2d 912, 921 (7th Cir. 1953) (requiring election between patenting and secrecy). For complications of this general rule, compare Rhone-Poullenc Agro, S.A. v. DeKalb Genetics Corp., 272 F.3d 1335, 1359 (Fed. Cir. 2001) (“Typically, the publication of a patent terminates all trade secret rights.”), with Evans Cooling Sys. v. General Motors Corp., 125 F.3d 1448, 1454 (Fed. Cir.
points reinforce the idea that not merely express allegations of copying, but allegations of facts that might involve copying, are surprisingly rare.

Finally, it is quite possible that even where defendants are engaged in copying, the plaintiffs may not know of that copying at the time they file their complaints. To try to assess this, we evaluated changes in allegations to see whether amended complaints added allegations of willfulness or copying. Only two amended complaints added allegations of copying, and only three added allegations of willfulness. While it is of course possible that plaintiffs discovered evidence of copying too late to amend the complaint, or discovered it but decided not to amend the complaint, for the reasons we suggested above we think plaintiffs who were already amending their complaints would likely have been motivated to add those allegations if possible. 108

Patent infringement, like most causes of action in the federal system, is governed by the relatively lax rules of notice pleading. 109 As a result, it is possible that plaintiffs simply do not include allegations either of copying or of the facts that might give rise to copying, opting instead for a simple complaint that merely identifies the patent and the defendant’s product. As noted above, we think there are substantial reasons to allege copying when the plaintiff has evidence of it.

Nonetheless, we acknowledge that the data in this Section may undercount the number of cases in which plaintiffs believe defendants have copied their invention, because some of those plaintiffs may simply not have mentioned that fact in their complaints.

To guard against this possibility, we collected 102 actual reported decisions that litigate issues involving evidence of copying. 110 For each of those decisions, we then collected the associated complaints from IPLC and ran the same analysis we ran on the randomly

1997) (invalidating a patent based on public use by an alleged thief; the court reasoned that the patentee could have filed a trade secret claim).
108. There is also the possibility that a defendant did in fact copy, but evidence of copying was never discovered. However, such a situation is highly unlikely given the incentive to label the infringer a “copier” and the broad scope of discovery under the federal rules. See supra notes 62–67 and accompanying text.
110. There were 107 cases collected, but in two cases the files were corrupted, and in three cases the complaints were unavailable. We discuss the results of those decisions in Part II.B infra.
selected complaints. This should provide a useful check on the problem of underpleading; if copying is not alleged in these complaints, which ultimately involve litigation of copying issues, it would suggest that our approach might be missing some substantial evidence of copying.

We report the aggregate results in Table 2.

**Table 2: Copying Allegations in Complaints Where Copying Is Ultimately Litigated**

<table>
<thead>
<tr>
<th></th>
<th>Total Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Willfulness Alleged</td>
<td>68 (66.7%)</td>
</tr>
<tr>
<td>Actual Notice Prior to Threat</td>
<td>44 (43.1%)</td>
</tr>
<tr>
<td>Copying Alleged</td>
<td>96 (94.1%)</td>
</tr>
<tr>
<td>Prior Business Dealings</td>
<td>9 (8.8%)</td>
</tr>
<tr>
<td>Trade Secrets</td>
<td>4 (3.9%)</td>
</tr>
<tr>
<td>Departing Employees</td>
<td>1 (1.0%)</td>
</tr>
<tr>
<td>Changes in Allegations</td>
<td>6 (5.9%)</td>
</tr>
</tbody>
</table>

These results confirm that, for allegations of copying, complaints are nearly as good a metric as written opinions. Of those cases where allegations of copying appeared in an opinion, almost all of the complaints also included such allegations—94.1% to be exact. This means that in only 5.9% of the cases did an allegation of copying appear in a district court opinion but not in the corresponding complaint for the case. There is, therefore, good reason to believe that if a patent case involves questions of copying that are mentioned in a decision, these allegations also appear in the complaint.

To make sure this cross-check is not skewed by the certainty of copying in ANDA cases pursuit to our coding methodology, we backed ANDA cases out of the analysis. The percentage changes slightly, but not much, when ANDA cases are removed. Of the 102 cases where the complaints were examined, 55 were ANDA cases—which are coded as cases alleging copying. Of the remaining 47 cases, 41 included allegations of copying both in the complaint and the written opinion—87.23%.

111. It is worth noting that a Fisher’s Exact Test looking at the difference between allegations of copying appearing in the complaint dataset compared to the opinion dataset produces a two-tailed p-value of 0.0290.

112. Fisher’s Exact Test produces a two-tailed p-value of 0.0264.
B. Court Findings of Copying

To get further evidence of copying in patent cases, we turn from complaints to decided cases.

1. Data Collection

In order to measure actual findings of copying in patent cases, we looked at district court opinions available on WESTLAW.\textsuperscript{113} We collected an initial set of opinions that included all opinions in cases involving an allegation of patent infringement issued on January 1, 2006 to February 29, 2008.\textsuperscript{114} We then searched the resulting set of opinions to identify situations where there were multiple opinions issued during the defined time period for a single case. Multiple opinions for a single case were collapsed to one “case” entry.\textsuperscript{115} As a result, we had a final dataset that included 1,871 patent infringement cases in which opinions were published on WESTLAW during a 26-month period.\textsuperscript{116}

\textsuperscript{113} The search was done on WESTLAW’s U.S. District Courts Cases (“DCT”) database. The DCT database “has all available federal district court cases with coverage beginning in 1945.” See WESTLAW Scope for the DCT database. “All available” is misleading—the database includes all those opinions that WESTLAW wishes to make electronically available. This includes all opinions found in the Federal Supplement series published by WESTLAW and other opinions that WESTLAW chooses to publish.

\textsuperscript{114} The specific search to capture this set of data was “PATENT /3 INFRING! & da(aft 12/31/2005 & bef 3/1/2008).” The results from this search were then reviewed to remove those opinions that did not involve actual allegations of patent infringement.

We treated as involving allegations of patent infringement both claims of patent infringement appearing in the complaint and counterclaims of the same. An opinion was deemed to contain an allegation of patent infringement even if the patent infringement claim had been dismissed or adjudicated prior to the opinion’s issuance. Claims of infringement based solely on design or plant patents were not considered “patent infringement cases” for the purposes of this study.

\textsuperscript{115} Weighting by cases rather than opinions makes sense so as to not overweight those cases where there are multiple opinions.

\textsuperscript{116} In comparison to the sampling study used to examine complaints, we used a population study when looking at opinions. As one author has previously noted, it is difficult, if not impossible, to generate a random, representative sample using reported cases. See John R. Allison & Mark A. Lemley, Empirical Evidence on the Validity of Litigated Patents, 26 AIPLA Q.J. 185, 194 n.20 (1998) (“[W]hen using reported cases as data sources, there are intractable problems with treating the grouping of cases as a representative random sample, regardless of how carefully one has defined the grouping. Although it is self-evident that any grouping of cases represents a subset of something larger, i.e., a population of something, it is practically impossible to assure that the grouping is a representative sample, much less a random one.”).

A population study can both be used to generate descriptive data and predictions—the predictions coming from “treating the population as a subset of a
We then coded the patent infringement opinions for these cases in the following three ways. First, we identified opinions mentioning allegations of copying.\textsuperscript{117} We used the same liberal approach for identifying allegations of copying as we did when coding complaints.\textsuperscript{118} We further investigated opinions that included allegations of copying to determine whether copying was actually proven.\textsuperscript{119} A finding of copying for the purposes of this study included only those findings that the patented invention was copied.\textsuperscript{120}

\textsuperscript{117} We did this in a two-step process. We began with a keyword search. For example, the dataset was searched for the presence of the words "copying," "copied," "copy," "duplicat!," "imitat!," "counterfeit!," "forger!," "steal!," and "stole!" within the same paragraph as the word "patent." Then the results of that search, and others, were examined by hand to gain a full understanding of whether the copying of the patented technology, if any, was alleged. In the end, while the initial searches were quite broad as to what trigger words would find discussion of copying, the word itself—"copy" and its derivatives—found almost all copying discussions in the dataset. This is not to say that other copying-related words did not also appear in the same opinion, merely that adding those words did not bring in many additional cases.

\textsuperscript{118} What makes this approach even more likely to overcount instances of copying is the possibility that judges are using terms such as "copying" rhetorically, as opposed to literally. See supra Part I.B.3.

\textsuperscript{119} A finding of copying took many forms, from the result of a bench trial to an admission by the defendant. See, e.g., Erico Int'l Corp. v. Doc's Mktg., Inc., No. 1:05cv2924, 2006 WL 1174259, at *5 (N.D. Ohio May 3, 2006) ("Here, Defendant openly has admitted that it engaged in direct copying of the Plaintiffs patented products."). In an ANDA case, copying was considered "found" if infringement was found.

\textsuperscript{120} By contrast, an opinion that found copying of non-patented aspects of the plaintiffs technology, while coded as an allegation of copying, was not coded as a finding of copying for the purposes of this study. See, e.g., Asyst Techs., Inc. v. Empak, Inc., No. C 98-20451 JF, 2006 WL 3302476, at *3 (N.D. Cal. Nov. 14, 2006) (noting that copying of a non-claimed feature was irrelevant to the question of willful infringement). Our definition
Second, we made a separate pass through the dataset of patent infringement cases to identify cases that involved allegations of willful infringement.\textsuperscript{121} For those cases containing allegations of willful infringement, we determined whether the allegation was decided, and if so, whether willful infringement was found or not.\textsuperscript{122} We also coded the willfulness cases by industry.\textsuperscript{123}

Third, we conducted a final search of the patent infringement dataset to identify all opinions mentioning allegations of infringement based on filings of an ANDA—that is infringement under 35 U.S.C. § 271(e)(2)(A).\textsuperscript{124}

2. Data on Claims of Copying

Out of the 1,871 patent infringement opinions in the dataset, 129 of them (6.89\%) included an allegation of copying that was mentioned in an opinion. Of these 129 cases, the allegation of copying was based on the filing of an ANDA in a little over half of the cases—78 (60.47\%) of the cases.\textsuperscript{125} Copying was actually found in 33 cases (25.58\%), with the finding occurring in 22 of the ANDA cases and 11 of the non-ANDA cases. When placed in the context of all of the patent infringement cases in the study, copying was established in only 1.76\% of all cases in the dataset.

A couple of observations can be made. First, the percentage of cases where copying was alleged dropped from 10.9\% when we looked at the complaints to 6.89\% when we looked at opinions.

---

\textsuperscript{121} We did this in two steps, just as with our coding of copying. We searched WESTLAW to identify discussions of willful infringement. For example, the dataset was searched for the presence of any derivative of the string “willful” within three words of the string “infring!.” Then, the results of that search, and others, were examined by hand to gain a full understanding of the willful infringement, if any, that was actually alleged.

\textsuperscript{122} For example, an allegation of willfulness was deemed “decided” if the opinion reported a jury verdict, bench trial determination, ruling on a judgment as a matter of law, or decision on summary judgment.

\textsuperscript{123} The same categories used in the early part of this Article were used here. See supra note 101 and accompanying text.

\textsuperscript{124} Again, this was done by searching WESTLAW—for example searching for the strings “ANDA” or “abbreviated new drug application”—and then processing those results by hand.

\textsuperscript{125} All ANDA cases were coded as cases alleging copying due to the nature of the § 271(e)(2)(A) claim. However, it is worth repeating, the copying necessary for filing an ANDA may not be copying of the patented technology.
Looking at the descriptive data, there appears to be a higher likelihood that an allegation of copying will appear in a complaint as opposed to a written decision.\textsuperscript{126} The most obvious explanation for this discrepancy is that allegations are just that—allegations—and not all will be proven in court. The difference may also reflect the fact that a district court has little reason, in many cases, to mention copying in a written opinion. For example, some decisions that involve claims of copying may not need to resolve the copying issue and therefore may not discuss it. It is also worth noting that the 6.89\% finding of allegations of copying in court decisions falls within the confidence interval (margin of error) of the percentage of complaints that include copying allegations.\textsuperscript{127}

Second, the fact that a little over half of the copying allegations and two-thirds of the findings of copying occurred in ANDA cases is explained by the nature of the ANDA patent litigation. This falls in line with the data from complaints, with around 60\% of cases alleging copying both in complaints and opinions being ANDA cases. As previously explained, ANDA cases inherently involve copying of the patentee’s product by the alleged infringer, and in most such cases the copying is of the patented technology.\textsuperscript{128} And when infringement is found, that infringement generally means that the patented invention was copied in the ANDA.

Finally, and most noteworthy, is the very small number of cases where copying was actually found. Such findings make up just over 1\% of the cases included in this part of our study. And if the ANDA cases are removed because of their unique linkage to copying, findings of copying drop to less than half a percent.

However, while the percentage of actual findings of copying may be low, there is also a real possibility of underreporting. Even if patentees want to argue copying, there is typically no reason for a court to mention copying in a patent infringement opinion because copying is irrelevant to the core issue in these cases—liability. In fact,

\textsuperscript{126} We performed a Pearson's Chi-Squared Test for statistical significance. See generally MICHAEL O. FINKELSTEIN & BRUCE LEVIN, STATISTICS FOR LAWYERS 157–62 (2d ed. 2001) (describing the Pearson's Chi-Squared Test). The data set was too large for a Fisher's Exact Test. A Pearson’s Chi-Squared Test produces a p-value of 0.04238, which means that the difference is statistically significant, but just barely.

\textsuperscript{127} See supra note 97 (noting that the confidence interval for the complaint incidents of alleged copying is 15.27\% \( > p > 6.49\% \)).

\textsuperscript{128} In other cases the patent may cover an inactive ingredient or a dissolution profile.
the Federal Circuit has admonished courts that discuss copying in the context of patent infringement.129

3. Data on Willful Infringement Findings

An alternative way to determine the amount of copying that actually takes place in patent infringement cases is to focus on those patent infringement cases where copying is explicitly relevant to the opinion being written. In opinions discussing patent issues where copying is relevant—in willfulness, inducement, or nonobviousness decisions for example—a court is more likely to be presented with evidence of copying and, in turn, more likely to mention and decide the question of copying the patent.130 The law makes copying relevant in these contexts, and therefore a litigant’s push to make copying an issue is more likely to be reflected in a written opinion (and it is extremely likely that plaintiffs who can allege or argue copying will do so). At the same time, just considering these cases would overstate the amount of copying, since copying is by definition far more likely to be raised in successful patent cases that involve willfulness allegations than in the litigation population at large.

As a result, we focused on cases involving allegations of willful infringement in order to estimate an upper bound on allegations and proof of copying in patent cases. In the dataset, there were 226 cases (12.08%) where an allegation of willful infringement was mentioned.131 An allegation of copying was mentioned or implied in 40 (17.70%) of these cases.132 A decision on willfulness was reported


130. See, e.g., Trading Techs. Int’l v. eSpeed, Inc., No. 04 C 5312 2008 WL 63233, at *2 (N.D. Ill. Jan. 3, 2008) (“[P]re-patent conduct is relevant to a determination of willfulness . . . when that pre-patent conduct consists of egregious copying (citing cases).”).

131. The difference between this result and that observed with allegations of willfulness in complaints is highly statistically significant, with a Pearson’s Chi-Square test producing a p-value < 0.0001. That is, it is significantly more likely that a complaint will contain an allegation of willfulness than an opinion. This observation is explained by the fact that a district court has no reason to mention an allegation of willful infringement unless the allegation is being decided. And the issue of willfulness is not addressed until most of the other issues in a given case are resolved in the patentee’s favor. Therefore, in the opinion data, there is likely significant underreporting of willfulness allegations.

132. As before, patent infringement claims based on the filing of ANDAs are treated as allegations of copying the patented technology.
in 77 (34.07%) of the 226 total cases. The split in results on willfulness was roughly 50-50—with willful infringement being found in 42 cases (54.55%) and not found in 35 cases (45.45%). Copying was alleged in 20 (25.97%) and found in 8 (10.39%) of the 77 cases deciding willfulness. A finding of copying resulted in a finding of willful infringement in 7 out of 8 cases (87.5%) where willfulness was actually decided. The remaining case finding copying had yet to decide the willfulness issue.\footnote{For example, in one case, copying was admitted, but the court had yet to decide the issue of willfulness. See \cite{Erico International Corporation v. Doc's Marketing, Inc., No. 1:05cv2924, 2006 WL 1174259, at *5 (N.D. Ohio May 3, 2006).}

Mentions of copying, both allegations and actual findings, were more prevalent in willfulness decisions (17.70%) than in the published decisions more generally (6.89%). And this difference is highly statistically significant.\footnote{The existence of copying allegations in willfulness cases is highly statistically significant, with a Pearson’s Chi-Square test producing a \( p \)-value < 0.0001.} This is not surprising given that copying is relevant to such an inquiry, but this result does differ from our complaint results, where there was no significant relationship between allegations of willfulness and allegations of copying.\footnote{The difference in statistical results between complaints and opinions is likely a continuation of the higher incident of willfulness allegations in complaints as compared to opinions. See supra note 131.}

But even here, the existence of copying allegations in published decisions did not rise dramatically, moving from 6.89% in the context of all of the cases to 17.70% in the context of only willfulness cases. The amount of copying found also did not jump significantly, rising from 1.76% in the context of all cases to 4.87% in the context of cases mentioning an allegation of willfulness. This view of the dataset may give us a better understanding of the amount of copying actually occurring in patent infringement cases given that courts have a reason to mention and decide the issue. The low percentages, however, still tell the same story as our earlier analysis—surprisingly little copying has occurred in these litigated cases.

It is also worth noting that when a court decides the willfulness issue and also finds copying, the court almost always deems the infringement willful. This data suggests that actual copying is good evidence of willful infringement. The one case in which copying did not support a finding of willfulness was an ANDA case.\footnote{See Janssen, L.P. v. Barr Labs., Inc., No. 07-1515 (JAP), 2008 WL 323558, at *3 (D. N.J. Feb. 4, 2008).} This is not
surprising, given that there is Federal Circuit case law holding that the action of filing an ANDA, by itself, is not evidence of willful infringement.\textsuperscript{137} District courts have repeatedly found no willful infringement even in light of the copying that accompanies an ANDA.\textsuperscript{138} The fact that—at least outside of ANDA cases—successful proof of copying overwhelmingly leads to a finding of willfulness bolsters our assumption that patentees have a strong incentive to allege and prove copying where they can.

The cases alleging willfulness can also be broken down by industry. Table 3 below depicts the industries involved in cases alleging willfulness. Specifically, Table 3 provides the number of cases for a given industry that involved allegations of copying and then actual findings of copying.\textsuperscript{139} For a given industry, percentages are provided that indicate the percentage of cases where willfulness was alleged, willfulness was found, copying was alleged, and copying was found.

\textsuperscript{137} See Yamanouchi Pharm. Co. v. Danbury Pharmacal, Inc., 231 F.3d 1339, 1347 (Fed. Cir. 2000) ("An ANDA filing by its very nature is a ‘highly artificial act of infringement,’ therefore, the trial court need not have elevated the ANDA certification into a finding of willful infringement.") (quoting Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661, 678 (1990)).

\textsuperscript{138} See, e.g., Janssen, L.P., 2008 WL 323558, at *3 n.1 (citing eight district court opinions where an allegation of willful infringement was dismissed because it was based solely on the act of filing the ANDA).

\textsuperscript{139} The numbers are bigger than the total number of cases observed because of the fact that the invention in one case can involve multiple industries.
Table 3: Copying by Industry in Cases Including Willfulness Allegations

<table>
<thead>
<tr>
<th>Industry</th>
<th>Willfulness Alleged</th>
<th>Willfulness Found</th>
<th>Copying Alleged</th>
<th>Copying Found</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmaceutical</td>
<td>15</td>
<td>0 (0%)</td>
<td>15 (100%)</td>
<td>3 (20%)</td>
</tr>
<tr>
<td>Medical Devices</td>
<td>23</td>
<td>3 (13.04%)</td>
<td>6 (26.08%)</td>
<td>2 (8.7%)</td>
</tr>
<tr>
<td>Biotechnology</td>
<td>15</td>
<td>4 (26.67%)</td>
<td>3 (20%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Computer-related</td>
<td>67</td>
<td>14 (20.90%)</td>
<td>4 (5.97%)</td>
<td>1 (1.49%)</td>
</tr>
<tr>
<td>Software</td>
<td>46</td>
<td>9 (19.57%)</td>
<td>3 (6.52%)</td>
<td>1 (2.17%)</td>
</tr>
<tr>
<td>Semiconductor</td>
<td>8</td>
<td>1 (12.5%)</td>
<td>1 (12.5%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Electronics</td>
<td>24</td>
<td>5 (20.83%)</td>
<td>2 (8.33%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Chemistry</td>
<td>30</td>
<td>1 (3.33%)</td>
<td>18 (60%)</td>
<td>3 (10%)</td>
</tr>
<tr>
<td>Mechanics</td>
<td>93</td>
<td>20 (21.51%)</td>
<td>13 (13.98%)</td>
<td>7 (7.53%)</td>
</tr>
<tr>
<td>Acoustics</td>
<td>1</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Optics</td>
<td>9</td>
<td>1 (11.11%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Automotive</td>
<td>8</td>
<td>2 (25%)</td>
<td>2 (25%)</td>
<td>1 (12.5%)</td>
</tr>
<tr>
<td>Energy</td>
<td>5</td>
<td>2 (40%)</td>
<td>1 (20%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Communications</td>
<td>9</td>
<td>3 (33.33%)</td>
<td>1 (11.11%)</td>
<td>1 (11.11%)</td>
</tr>
</tbody>
</table>

This data mimics the results from complaint data in most respects. As with complaints, pharmaceutical and chemical cases make up a large portion of those cases mentioning allegations of copying and finding actual copying. On the other end of the spectrum are computer-related and software cases, where there was a large number of cases alleging willful infringement, but a small number of allegations and findings of copying. As with our findings with respect to complaints, there is a highly statistically significant difference between allegations of copying in pharmaceutical and chemical cases as compared to computer-related and software cases.\(^{140}\) Again, allegations are more likely to exist in pharmaceutical and chemical cases.

C. Interpreting the Data

None of these measures is perfect. Data based on complaints are in one sense likely to overstate the amount of copying, since it merely

\(^{140}\) A Pearson’s Chi-Square test produced a \(p\)-value of 0.0002.
requires that the plaintiff allege something even in general terms, not
that it be proven. On the other hand, that data may well understate
the amount of copying, because some plaintiffs may not include an
allegation of copying even if they believe it to have occurred, or may
find out about copying too late in the litigation to amend their
complaints. It is also possible that there is information flow that
doesn’t rise to the level of copying but still represents some sort of
“free riding” on the patentee’s product, though the incentives of
plaintiffs to argue copying when they can should mean that most such
cases get included within the broad definition of copying that we use.
The specific fact situations we associate with copying are similarly
both under- and over-inclusive; not every case of a departing
employee or a business deal gone bad will involve copying, and not
every case of copying will involve one of those facts.

Data based on actual litigation of willfulness in written decisions
reflects a different set of biases; it solves the undercounting and
mistaken allegations problems with complaints, but it overcounts
bench as opposed to jury trials, since the former are more likely to
result in a written opinion, and it may be subject to selection bias if
obvious cases of copying are disproportionately likely to settle before
resolution. Finally, willfulness cases standing alone are likely to
significantly overstate the percentage of copying, because both the
fact that the plaintiff won the infringement suit and the fact that the
plaintiff has alleged willful infringement are likely to be correlated
with an artificially high level of copying.

If each of these measures produced significantly different results,
we might conclude that those results reflected imperfections in the
proxies we used for copying. But the fact that all these diverse
methodologies produce largely consistent results (as summarized in
Table 4) gives us substantial confidence that copying is indeed rare in
patent litigation.

141. We thank Ted Sichelman for this point.
Table 4: Summary of Findings of Copying Across Measures

<table>
<thead>
<tr>
<th>Measure</th>
<th>Total Cases</th>
<th>Copying</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complaints</td>
<td>193</td>
<td>21</td>
<td>10.9</td>
</tr>
<tr>
<td>(Pharma)</td>
<td>20</td>
<td>13</td>
<td>65.0</td>
</tr>
<tr>
<td>(Non-pharma)</td>
<td>173</td>
<td>8</td>
<td>4.2</td>
</tr>
<tr>
<td>Decisions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allegations</td>
<td>1871</td>
<td>129</td>
<td>6.9</td>
</tr>
<tr>
<td>(Pharma)</td>
<td>78</td>
<td>78</td>
<td>100</td>
</tr>
<tr>
<td>(Non-pharma)</td>
<td>1793</td>
<td>51</td>
<td>2.8</td>
</tr>
<tr>
<td>Findings</td>
<td>1871</td>
<td>33</td>
<td>1.8</td>
</tr>
<tr>
<td>(Pharma)</td>
<td>78</td>
<td>22</td>
<td>28.2</td>
</tr>
<tr>
<td>(Non-pharma)</td>
<td>1793</td>
<td>11</td>
<td>0.6</td>
</tr>
<tr>
<td>Willfulness</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allegations</td>
<td>226</td>
<td>40</td>
<td>17.7</td>
</tr>
<tr>
<td>Findings</td>
<td>77</td>
<td>8</td>
<td>10.4</td>
</tr>
</tbody>
</table>

So does the fact that the cases that end up involving copying almost all involved allegations of copying in the complaints. That doesn’t mean we have captured every instance of copying; doubtless there are some we missed, perhaps because the plaintiffs themselves missed them. But it does suggest that the numbers we report are, while not perfect, pretty good approximations of the level of copying in the real world.

III. IMPLICATIONS OF THE DATA

A. Understanding Policy Debates and Reform Proposals

The rarity of copying in modern patent law has several implications for understanding current rhetorical debates, public policy discussions, and proposals for reform.

First, it should be evident that patent infringement can rarely, if ever, be equated with “theft” of physical property or even “piracy” of other types of IP. Public policy debates around patent reform often involve claims that any weakening of the patent right will destroy the patent system by encouraging widespread “theft” of patent rights.142

142. See, e.g., Edward M. Roche, Internet and Computer Related Crime: Economic and Other Harms to Organizational Entities, 76 Miss. L.J. 639, 644 (2007) (referring to the
But our data suggest that there is very little "theft" of patent rights going on right now—at least as it is represented in patent cases. Virtually every case filed—and even the overwhelming majority of those in which the plaintiffs win and claim that the defendant was a willful infringer—involves not theft or even copying with a legitimate effort to design around but independent development by the defendant. That doesn't mean that those defendants are not infringing, or that they shouldn't be held liable. Nor does it resolve the underlying debates over patent reform; just because no one is copying patented inventions now doesn't mean they wouldn't do so under a different legal regime. But it is simply inaccurate to speak of patent defendants as a whole as "unscrupulous copyists" or "thieves."  

The second implication for existing policy debates flows from the exception to what we just said. There are a few industries in which the defendants do in fact copy the invention from the plaintiffs—the pharmaceutical and chemical industries. In those industries, the majority of cases involve allegations of copying. Indeed, in the pharmaceutical industry most patent infringement suits are filed against generic companies that file an ANDA application with the FDA in which they effectively admit that they have copied the plaintiff's drug (though not necessarily the plaintiff's patent) in order to show bioequivalence between the two products.

The contrast between the pharmaceutical industry and the rest of the patent world, and particularly the information technology industries, will be a familiar one to those who have been following the years-long debate over patent reform. On issue after issue, the biopharmaceutical and the IT industries have lined up on opposite sides of the debate, effectively stifling legislative patent reform. Dan Burk and Mark Lemley have argued that this split results from


fundamentally different industry characteristics. Our data provides a significant new piece of evidence to support that view. The IT industries, which faced a majority of the lawsuits in our samples, were virtually never accused of actually copying their products from the patent owner. Their perspective on strong patent enforcement rules will accordingly be quite different than that of companies in an industry in which copying is the norm in infringement suits.

Finally, our data shed some light on the growing chorus of calls for an independent development defense, which currently does not exist in the United States. A number of scholars have argued that patent law should exempt independent development and instead target only copying, just as copyright and trade secret law do. One of us has expressed some skepticism over that proposal. Our data demonstrates precisely how much is at stake in this debate. A patent infringement system that punished only copying would look dramatically different than current law. Ninety percent of patent lawsuits would go away, and most patent litigation would be in the chemical and pharmaceutical industries. Some will suggest this would be a good idea. We express no opinion on that issue here, other

145. See supra note 72 and accompanying text.
146. See, e.g., Maurer & Scotchmer, supra note 3, at 535; Carl Shapiro, Prior User Rights, AM. ECON. REV., May 2006, at 92; Vermont, supra note 72, at 484; John S. Liebowitz, Note, Inventing a Nonexclusive Patent System, 111 YALE L.J. 2251, 2286–87 (2002). Others have suggested that inadvertent infringers should pay only compensatory damages, not face injunctive relief. See Henry E. Smith, Intellectual Property as Property: Delineating Entitlements in Information, 116 YALE L.J. 1742, 1818–19 (2007) (noting that if "the problem of good-faith 'encroachment' became serious enough in patent law, a limited good-faith user defense with damages rather than injunctive remedies would be appropriate." But as Mike Carrier has observed, such a rule would effectively end injunctive relief in the overwhelming majority of patent cases, something Smith would likely oppose. See Michael A. Carrier, Why Modularity Does Not (and Should Not) Explain Intellectual Property, 117 YALE L.J. POCKET PART 95, 99 (2007), http://yalelawjournal.org/images/pdfs/592.pdf ("Smith does not explain how his enthusiasm for injunctions addresses these problems, makes sense in light of reasonable patent trends moving in the other direction, or is consistent with his preference for a damages remedy for inadvertent infringers.").
147. See supra notes 83–86 and accompanying text (setting forth the specific critique of such a defense).
148. Jim Bessen and Mike Meurer, for example, present data suggesting that the patent system is only working in those industries. JAMES BESSEN & MICHAEL J. MEURER, PATENT FAILURE: HOW JUDGES, BUREAUCRATS, AND LAWYERS PUT INNOVATORS AT RISK 15 (2008).
than to point out precisely how different such a patent system would be from the one we have today.

B. Calibrating Patent Damages

Our findings bear on one significant set of judicial and policy debates—those over the appropriate measure of damages in patent infringement cases. Unlike copyright and trade secret law, which provide that prevailing plaintiffs can recover not only for their own losses but also the defendant's gains, and in some cases far more than that, patent law since at least 1946 has limited the award of damages to those adequate to compensate the plaintiff for its losses. Compensatory patent damages take one of two forms—lost profits, if the plaintiff can prove she lost profits, and a reasonable royalty in all other cases.

In recent years, courts have awarded greater and greater damages under the reasonable royalty theory, in part because they have ignored mechanisms designed to avoid overcompensation in complex industries but in part also because they were influenced by the perceived need to deter infringement. In Monsanto Co. v. McFarling, for example, the court affirmed an award of "reasonable" royalties more than six times the actual royalty charged for use of patented seeds, in part to avoid a "windfall" to the infringer and in part because "of the savings Mr. McFarling achieved by his infringement, the benefits to Monsanto from requiring farmers to adhere to the terms of its standard licensing agreement, and the benefits conferred by the patented technology over the use of

150. 17 U.S.C. § 504(c) (providing for statutory damages that can exceed actual damages by a factor of thousands in extreme cases).
151. 35 U.S.C. § 284 was amended in 1946 to eliminate the disgorgement remedy.
152. See Panduit Corp. v. Stahlin Bros. Fibre Works, Inc., 575 F.2d 1152, 1157 (6th Cir. 1978) ("When actual damages, e.g., lost profits, cannot be proved, the patent owner is entitled to a reasonable royalty.").
154. 488 F.3d 973 (Fed. Cir. 2007). One of the authors represented McFarling in this case.
conventional seeds." In so doing, the court imported the concept of unjust enrichment into the damages calculation. And in other cases the Federal Circuit has similarly granted reasonable royalty awards that significantly exceed the amount required to compensate patent owners. At least in part, those decisions, too, have done so to deter patent infringement, as in *Monsanto Co. v. Ralph*. But even where deterrence is not an explicit rationale, the court seems increasingly to consider the profit the defendant makes from infringement to be fair game in the reasonable royalty calculus, as in *McFarling* and *Golight*.

Our data suggest that the incorporation of unjust enrichment and deterrence concepts into reasonable royalty law is a mistake. With very few exceptions, defendants are not making a calculated decision to infringe a patent. The overwhelming majority of defendants are independent developers who were unaware of the existence of the patent when they made their product design decisions. And those who were aware of the patent and made a decision to infringe are mostly generic pharmaceutical companies subject to a special set of rules that make the application of reasonable royalty law implausible in the extreme. Less than 4% of complaints in our database even

---

155. *Id.* at 980–81 (emphasis added).


157. 382 F.3d at 1384. To be sure, there was substantial reason to believe that Ralph was a bad actor. For a discussion of the role of intent in damages theory, see, for example, Roger D. Blair & Thomas F. Cotter, *Rethinking Patent Damages*, 10 TEX. INTELL. PROP. L.J. 1, 5–44 (2001), and Paul J. Heald, *Optimal Remedies for Patent Infringement: A Transactional Model*, 45 HOUS. L. REV. 1165, 1185–87 (2008).

158. Some scholars have expressly argued for this approach, suggesting that because an "option to infringe" is valuable to the defendant, that value needs to be conveyed to the patentee. Jerry A. Hausman et al., *Patent Damages and Real Options: How Judicial Characterization of Noninfringing Alternatives Reduces Incentives to Innovate*, 22 BERKELEY TECH. L.J. 825, 830–31 (2007).

159. In pharmaceutical patent cases, the generic must notify the patentee before selling a generic product, and the patentee is entitled to an automatic thirty-month stay of those sales pending its infringement suit. 21 U.S.C.A. § 355(j)(5)(B)(iii)(IV) (West Supp. 2008); § 355(j)(5)(B)(iii). If that thirty-month period expires, courts can enter preliminary injunctions, and, even if they don't, generic companies are often afraid to enter the market "at risk." As a result, most pharmaceutical patent cases never involve claims of damages at all. And if they do, those damages will almost certainly be the patent owner's lost
involve allegations of copying that might justify a deterrence-related “kicker” of the sort that is increasingly showing up in Federal Circuit case law. For the same reason, the scholarship that suggests treating the “choice” to infringe as a real option for which the infringer should have to pay misses the point: overwhelmingly, infringers are not choosing to infringe, but are designing products in ignorance of the patent in ways that are later found to infringe.

We aren’t suggesting that damages aren’t appropriate for patent infringement—far from it. But deterrence and unjust enrichment are concepts designed to punish and therefore discourage infringement; they have no place in a patent regime where virtually all infringement is unintentional.

In the rare cases where infringement is intentional, patent law provides for treble damages for willful infringement. A second finding in our data, though, is that “willfulness” as the term is used in patent law bears little resemblance to intentional copying. To begin, we note that 157 of 193 plaintiffs (81.3%) in our complaint database alleged willfulness even though only 21 alleged copying—establishing no statistically significant relationship between allegations of willfulness and copying. And while we did find a statistically significant relationship between these two allegations in the opinion

---

160. Panduit Corp. v. Stahlin Bros. Fibre Works, Inc., 575 F.2d 1152 (6th Cir. 1978), established the concept of a “kicker” to account for otherwise-uncompensated losses. Id. at 1158–59. The Federal Circuit rejected the kicker idea in Mahurkar v. C.R. Bard Co., 79 F.3d 1572, 1581 (Fed. Cir. 1996) (finding that no “kicker” is permissible on top of the reasonable royalty to compensate for attorney’s fees or litigation expenses; patentee must prove case is exceptional to recover such expenses), but has reimported it under other names. See, e.g., King Instruments Corp. v. Perego, 65 F.3d 941, 951 n.6 (Fed. Cir. 1995) (permitting “[d]iscretionary increases”); Stickle v. Heublein, Inc., 716 F.2d 1550, 1563 (Fed. Cir. 1983) (allowing for “an increase in the reasonable royalty determined by the court”).


162. To be sure, one could envision a market in which patents were easy to identify, interpret, and license, and in such a hypothetical world it might make sense to require all companies to search for and license patents before beginning any research or production product. But we do not live in that world. See Mark A. Lemley, Ignoring Patents, 2008 MICH. ST. L. REV. 19, 19 (2008).

163. In re Seagate Tech. LLC, 497 F.3d 1360, 1368 (Fed. Cir. 2007) (en banc).

164. See supra note 99 and accompanying text (finding a p-value of 0.7077).
the percentage of cases where there was such a correlation was still very low (17.70%). The percentage stayed low when looking at cases where willfulness was actually decided, with only 20 (25.97%) of the cases deciding the willfulness issue mentioning an allegation of copying. And when willfulness was found, an allegation or finding of copying did not necessarily follow. In the 42 cases finding willful infringement, only 11 (26.19%) contained an allegation of copying and only 7 (16.67%) found copying. In fact, two cases found willful infringement while explicitly finding no copying.

This data suggests a mismatch between the goals of willfulness law—to deter intentional conduct—and its application in the courts. The Federal Circuit changed the standard for willfulness in 2007 and now requires proof of “objective recklessness”—a standard still less than intentional conduct but more stringent than the duty of due care that preceded it. It remains to be seen whether this new standard will bring claims of willfulness more in line with the subset of cases involving claims of intentional conduct.

C. Patents, Disclosure, and Technology Transfer

Our data may also shed some light on the role of the patent system in encouraging technology transfer. The patent cases we studied were not, by and large, cases about a defendant learning the invention from the plaintiff. That doesn’t mean that technology transfer from patentees to others—or even copying of inventions—doesn’t happen in the patent system, of course. We expect that patent licensing involves technology transfer (as opposed to merely an agreement to forebear from suit) in a wide variety of contexts, from university licenses to start-ups to joint ventures to international

165. See supra note 134 and accompanying text (finding a p-value of < 0.0001).

166. As a point of contrast, James Bessen and Michael Meurer found that 44% (30 of 68) of cases finding willfulness included a finding of copying. See BESSEN & MEURER, supra note 148, at 277 n. 5. Bessen and Meurer’s numbers come from a much older dataset—compiled in 2000 by now Judge Kimberly Moore. Id.


168. Seagate, 497 F.3d at 1371.
outsourcing of production. But it does suggest that patent litigation today is not about policing failed efforts at technology transfer, but rather about efforts by patent owners to enforce their right of exclusivity or to collect revenue from independent creators. As a corollary, it may well be that judicial or legislative efforts to curb abuse of patent litigation will have no significant adverse effect on the technology transfer function of the patent system, though it is important to make sure that efforts to limit the very real problem of litigation abuse don’t spill over into attacks on patent rights more generally.

Our data do provide some inferential support for those who have argued that the disclosure function of the patent system isn’t working terribly well. Most defendants in patent infringement lawsuits are not copiers—meaning they were not knowingly using already-patented technology as the basis for an improvement or attempting to design-around a patented technology. This should not be surprising. A variety of evidence already suggests that scientists in most industries rarely read patents, and that even if they did, those patents aren’t a particularly good means of conveying technical information. The fact that few, if any, people appear to be copying technology from patent owners is consistent with this argument, though it is not proof that people aren’t copying inventions after the expiration of their patents, copying patents and then voluntarily paying licenses, or successfully designing-around.

D. Choosing Between Patents and Trade Secrets

Finally, our results have implications for the relationship between patents and trade secrets. The traditional approach to this relationship, both by courts and commentators, views inventors as choosing between patent and trade secret protection. In the traditional view, patents are superior to trade secrets because they


give the public the benefit of the invention, and so the law weakens trade secret protection sufficiently that users are inclined to choose patent protection instead. Similarly, in this view, if patent law is weakened too much, inventors will choose instead to rely on secrecy, and the public domain will be impoverished as a result.

Our findings cast substantial doubt on this traditional story. Trade secret law punishes only misappropriation of one’s ideas by another—that is, copying. Because patent plaintiffs are overwhelmingly suing to prevent independent development, trade secret law would not help them. Further, in the only class of cases where defendants are copying the plaintiff’s invention with great regularity—pharmaceutical cases—the regulatory structure of the market will likely preclude reliance on trade secret law. As a result, patent litigants don’t face much of a choice. No matter how much patent law is weakened, they are unlikely to switch to secrecy, because secrecy doesn’t give them what they want from the patent system.

CONCLUSION

Patents are fundamentally different from other types of IP rights. The patent litigation system does not appear to operate to prevent copying. Instead, it gives patent owners control primarily over independent invention by third parties. There may be good reasons to give patent owners this control, whether to give inventors extra incentives or perhaps to create more certain rights that more easily can be licensed. But debates over the patent system—and legal rules that set remedies for infringement—should not be based on the assumption that patent infringers are “thieves” or “copiers.” The evidence we offer in that paper suggests that that assumption is wrong.

172. See, e.g., Kewanee Oil, 416 U.S. at 489–90. For a discussion of the choices actually made by inventors, which are more complicated, see Mark A. Lemley, The Surprising Virtues of Treating Trade Secrets as IP Rights, 61 STAN. L. REV. 311, 338–41 (2009).

173. There is, however, a question about an inventor’s perception on the front-end. If the rhetoric of copying is as strong as it seems to be, there might be reason to believe that inventors think (wrongly, as our data establishes) that the value in the patent lies in keeping out potential copyists. Inventors may have the misperception that patent law’s capturing of independent creation is only a marginal benefit. For those inventors with this perception, opting for trade secrecy is a real (if misguided) possibility.